

## RESEARCH ARTICLE

# Risk of diabetes mellitus among users of immune checkpoint inhibitors: A population-based cohort study

Jeffrey Shi Kai Chan<sup>1</sup>  | Sharen Lee<sup>1</sup> | Dicken Kong<sup>1</sup> | Ishan Lakhani<sup>1</sup>  | Kenrick Ng<sup>2</sup> | Edward Christopher Dee<sup>3</sup>  | Pias Tang<sup>1</sup> | Yan Hiu Athena Lee<sup>1</sup>  | Danish Iltaf Satti<sup>1</sup> | Wing Tak Wong<sup>4</sup> | Tong Liu<sup>5</sup>  | Gary Tse<sup>5,6,7</sup>

<sup>1</sup>Cardio-Oncology Research Unit, Cardiovascular Analytics Group, Hong Kong, China

<sup>2</sup>Department of Medical Oncology, University College London Hospitals NHS Foundation Trust, London, UK

<sup>3</sup>Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA

<sup>4</sup>School of Life Sciences, The Chinese University of Hong Kong, Hong Kong, China

<sup>5</sup>Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China

<sup>6</sup>Kent and Medway Medical School, University of Kent and Canterbury Christ Church University, Canterbury, Kent, UK

<sup>7</sup>School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong Kong, China

## Correspondence

Tong Liu, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China.

Email: [liutongdoc@126.com](mailto:liutongdoc@126.com)

Gary Tse, Kent and Medway Medical School, University of Kent and Canterbury Christ Church University, Canterbury, Kent CT2 7FS, UK.

Email: [gary.tse@kmms.ac.uk](mailto:gary.tse@kmms.ac.uk)

## Funding information

Tianjin Key Medical Discipline (Specialty) Construction Project, Grant/Award Number: TJYXZDXK-029A

## Abstract

**Background:** Immune checkpoint inhibitors (ICIs) are increasingly established cancer therapeutics, but they are associated with new-onset diabetes mellitus (DM). Such risks have not been adequately quantified, and between-class and -sex differences remain unexplored.

**Methods:** This was a prospective cohort study of cancer patients receiving any ICI in Hong Kong between 2013 and 2021. Patients with known DM were excluded. Due to few patients using other ICIs, only programmed cell death 1 inhibitors (PD-1i) and programmed death ligand 1 inhibitors (PD-L1i) were compared, alongside between-sex comparison. When comparing PD-1i against PD-L1i, patients with the use of other ICIs or both PD-1i and PD-L1i were further excluded. Inverse probability treatment weighting (IPTW) was used to minimize between-group covariate imbalances.

**Results:** Altogether, 3375 patients were analyzed (65.2% males, median age 62.2 [interquartile range 53.8–69.5] years old). Over a median follow-up of 1.0 [0.4–2.4] years, new-onset DM occurred in 457 patients (13.5%), with a 3-year risk of 14.5% [95% confidence interval 13.3%, 15.8%]. IPTW achieve acceptable covariate balance between sexes, and between PD-1i ( $N = 622$ ) and PD-L1i ( $N = 2426$ ) users. Males had significantly higher risk of new-onset DM (hazard ratio 1.35 [1.09, 1.67],  $p = 0.006$ ), while PD-1i and PD-L1i users did not have significantly different risks (hazard ratio vs PD-L1i 0.81 [0.59, 1.11],  $p = 0.182$ ). These were

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2023 The Authors. *Cancer Medicine* published by John Wiley & Sons Ltd.

consistent in those with at least 1 year of follow-up, and on competing risk regression.

**Conclusion:** Users of ICI may have a substantial risk of new-onset DM, which may be higher in males but did not differ between PD-1i and PD-L1i.

#### KEYWORDS

competing risk, CTLA-4, diabetes, immune checkpoint inhibitors, PD-1, PD-L1

## 1 | INTRODUCTION

Over the past decade, immunotherapy has revolutionized the field of oncology, providing novel, efficacious alternatives to conventional management strategies in the treatment of numerous advanced-staged malignancies.<sup>1</sup> Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that function by relieving the tumor-mediated inhibition on T-cell activity, thereby amplifying the antitumor capacity of such immune cells to suppress metastatic progression and improve long-term patient outcomes. In particular, ICIs target the cytotoxic T lymphocyte antigen 4 (CTLA-4)-CD28 axis or the programmed cell death 1 (PD-1) – programmed death ligand 1 (PD-L1) axis. With PD-1 protein being highly expressed on the surface of activated T cells, overexpression of PD-L1 allows some malignant cells to evade immunosurveillance mechanisms through PD-1/PD-L1 interaction, which may be prevented by PD-1 and PD-L1 inhibitors (PD-1i and PD-L1i).<sup>2</sup>

However, the role of the PD-1/PD-L1 pathway in the maintenance and regulation of immune tolerance implies that PD-1i/PD-L1i may lead to a loss of self-tolerance,<sup>3</sup> resulting in various immune-related adverse events. Meanwhile, CTLA-4 inhibitors (CTLA-4i) may cause immune-related adverse events via a number of complex pathways, including but not limited to increased T cell cytokine receptor expressions, and T cell hyper-responsiveness due to reduced attenuation of major histocompatibility complex receptor signaling on T cells.<sup>4,5</sup> Immune-related adverse events may also relate to abnormal activation of B cells and thus generation of autoantibodies,<sup>5</sup> such as antibodies against islet cell antigens and glutamic acid decarboxylase-65 which may cause diabetes mellitus (DM).<sup>6,7</sup> Overall, CTLA4i have more widespread and rapid effects due to their activation of T nodes from lymph nodes and their “enhancement” of immune responses,<sup>5,8,9</sup> contrasting the predominant modulation of peripheral T cells by PD1i and PDL1i and their “normalization” of immune responses.<sup>5,8,9</sup> Such differences also meant that the types of toxicities differ between CTLA4i and PD1i / PDL1i, with the former predominantly associated with inflammation of colon, skin, and pituitary, and the latter predominantly associated with inflammation of thyroid, muscles, joints, lungs, and skin.<sup>8</sup>

Owing to the autoimmune nature of these events, they may affect a wide range of organ systems, resulting in cutaneous, gastrointestinal, pulmonary, hepatic, neurological, cardiac, and endocrine manifestations.<sup>10–14</sup> As above mentioned, these include DM,<sup>6,7,15,16</sup> which, given its well-known detrimental effects on multiple organ systems, may add substantially to the morbidity of patients using ICIs. Nonetheless, as a relatively new endocrinopathy, the risk of new-onset DM in patients receiving ICIs has not been adequately quantified, and it remains unclear whether there are differences in the risk of new-onset DM between different types of ICIs. Additionally, while studies have suggested that the efficacy of ICIs may differ between sexes, it remains unclear whether the risk of new-onset DM among users of ICIs exhibits such differences.<sup>17,18</sup> Therefore, this study aimed to quantify the risk of developing DM in cancer patients treated with ICIs, and to compare the risk of new-onset DM between sexes and different types of ICIs.

## 2 | METHODS

This study was approved by The Joint Chinese University of Hong Kong—New Territories East Cluster Clinical Research Ethics Committee. It was in line with the Strengthening the Reporting of Observational Studies in Epidemiology guideline and the Declaration of Helsinki. The requirement for individual patient consent was waived as only retrospective, deidentified data were used. All underlying data are available on reasonable request to the corresponding authors.

### 2.1 | Data source

Data were extracted from the Clinical Data Analysis and Reporting System (CDARS), a prospective, population-based electronic medical database capturing the basic demographics, diagnoses, laboratory investigations, and medical procedures of all patients attending public hospitals and clinics in Hong Kong, which cover the whole territory of Hong Kong and serve approximately 90%

of the population.<sup>19</sup> CDARS records diagnoses using the International Classification of Diseases, Ninth revision (ICD-9) codes, as ICD-10 codes have not been used in CDARS to date. Mortality data were acquired from the linked Hong Kong Death Registry, a governmental mortality registry of Hong Kong citizens. Both databases have been used in previous studies, and have been demonstrated to have good coding accuracy and data completeness.<sup>20–24</sup>

## 2.2 | Patient population

All patients with cancer receiving any ICI in Hong Kong between January 1, 2013 and December 31, 2021 were identified. ICI included PD-1i (pembrolizumab or nivolumab), PD-L1i (atezolizumab, avelumab, or durvalumab), and CTLA-4i (ipilimumab); other ICI were not available in Hong Kong when this study was conducted. Patients with prior diagnosis of DM were excluded from the descriptive analysis of the burden of new-onset DM.

As very few patients ever used CTLA-4i, only PD-1i and PD-L1i were compared in this study. In this comparative analysis, patients who ever used both PD-1i and PD-L1i (including non-concurrent prescriptions), and those who used CTLA-4i were further excluded. No exclusion criteria were applied for the between-sex comparative analysis.

## 2.3 | Follow-up and outcome

All patients were followed up until December 31, 2021. The outcome of interest was new-onset DM. Throughout this study, DM was defined by ICD-9 codes (Table S1), usage of any anti-diabetic medication, any HbA1c measurement  $\geq 6.5\%$ , or any two consecutive fasting glucose measurements  $\geq 7.0$  mmol/L.<sup>25</sup>

## 2.4 | Data collected

The following data were collected for all patients: demographics (age and sex), type of cancer, comorbid conditions (hypertension (defined by both ICD-9 codes and use of antihypertensive(s)), ischemic heart disease, myocardial infarction, heart failure, atrial fibrillation, dyslipidemia (defined by both ICD-9 codes and use of anti-lipid medication(s)), chronic obstructive pulmonary disease, and stroke), and use of non-ICI medications (angiotensin-converting enzyme inhibitors or angiotensin receptor

blockers, beta-blockers, statins, dihydropyridine calcium channel blockers, chemotherapy, and steroids). There were no missing data.

## 2.5 | Statistical analyses

Continuous variables were expressed as median with interquartile ranges. The incidence rate of new-onset DM was estimated and described. The cumulative incidence of new-onset DM was modeled and visualized using the Aalen–Johansen method, with consideration of mortality as a competing event. Correspondingly, the 1-year, 2-year, and 3-year risks of new-onset DM were estimated and described.

In the separate comparisons between males and females and between PD-1i and PD-L1i, inverse probability treatment weighting (IPTW) was used to minimize imbalances in baseline characteristics between groups. The propensity scores were calculated using the *twang* package, with which a generalized boosted model with a maximum of 10,000 regression trees and an iteration stopping point minimizing the absolute standardized mean difference of the mean effect size were used, with all possible three-way interactions allowed. All recorded baseline covariates listed above were included in the IPTW, and were summarized in Table 1 (male vs. female) and Table S2 (PD-1i vs. PD-L1i). Standardized mean difference (SMD) was used to quantify inter-group balance of covariates, with SMD  $< 0.2$  considered to represent acceptable balance. The cause-specific cumulative incidence of new-onset DM was modeled and visualized using the Aalen–Johansen method, with consideration of mortality as competing event.<sup>26,27</sup> The Aalen–Johansen method was used instead of the Kaplan–Meier method, as the latter is known to over-estimate cumulative incidences in the presence of competing risks.<sup>28</sup> Univariable Cox regression with IPTW was used to compare treatment groups, with hazard ratio (HR) with 95% confidence interval as summary statistics.

Two a priori sensitivity analyses were done for each comparison. First, as DM occurring soon after ICI initiation may be due to premorbid conditions instead, a sensitivity analysis was performed limiting to those with at least 1 year of follow-up. Second, a sensitivity analysis was performed using Fine and Gray competing risk regression with the sub-distribution model to account for mortality; the sub-hazard ratio with 95% confidence interval was used as summary statistics.

All *p*-values were two-sided, and *p*  $< 0.05$  was considered statistically significant. All statistical analyses were performed on Stata v16.1 (StataCorp LLC, Texas, USA).

**TABLE 1** Characteristics of included patients, and balance in characteristics between male and female patients before and after inverse probability treatment weighting (IPTW).

	All patients	Females	Males	Pre-IPTW SMD	Post-IPTW SMD
Number of patients, <i>N</i>	3375	1173	2202	NA	NA
<i>Demographics</i>					
Age, years [interquartile range]	62.2 [53.8–69.5]	59.7 [50.9–67.5]	63.3 [55.6–70.3]	0.264	0.028
Male, <i>N</i> (%)	2202 (65.2)	0 (0)	2202 (100)	NA	NA
<i>Type of immune checkpoint inhibitor used</i>					
PD-1i, <i>N</i> (%)	2749 (81.5)	958 (81.7)	1791 (81.3)	0.009	0.010
PD-L1i, <i>N</i> (%)	691 (20.5)	237 (20.2)	454 (20.6)	0.010	0.018
CTLA-4i, <i>N</i> (%)	269 (8.0)	90 (7.7)	179 (8.1)	0.017	0.022
<i>Type of cancer</i>					
Head and neck cancers, <i>N</i> (%)	126 (3.7)	38 (3.2)	88 (4.0)	0.040	0.024
Lung cancer, <i>N</i> (%)	1595 (47.3)	510 (43.5)	1085 (49.3)	0.116	0.033
Melanoma, <i>N</i> (%)	90 (2.7)	46 (3.9)	44 (2.0)	0.119	0.035
Renal cell carcinoma, <i>N</i> (%)	124 (3.7)	31 (2.6)	93 (4.2)	0.084	0.025
<i>Comorbid conditions</i>					
Hypertension, <i>N</i> (%)	1292 (38.3)	405 (34.5)	887 (40.3)	0.118	0.019
Ischemic heart disease, <i>N</i> (%)	105 (3.1)	15 (1.3)	90 (4.1)	0.162	0.059
Myocardial infarction, <i>N</i> (%)	25 (0.7)	5 (0.4)	20 (0.9)	0.056	0.009
Heart failure, <i>N</i> (%)	25 (0.7)	6 (0.5)	19 (0.9)	0.041	0.019
Atrial fibrillation, <i>N</i> (%)	61 (1.8)	21 (1.8)	40 (1.8)	0.002	0.011
Dyslipidemia, <i>N</i> (%)	647 (19.2)	175 (14.9)	472 (21.4)	0.166	0.038
COPD, <i>N</i> (%)	86 (2.6)	3 (0.3)	83 (3.8)	0.223	0.117
Stroke, <i>N</i> (%)	43 (1.3)	14 (1.2)	29 (1.3)	0.011	0.007
<i>Medications used</i>					
ACEI/ARB, <i>N</i> (%)	509 (15.1)	136 (11.6)	373 (16.9)	0.149	0.046
Dihydropyridine CCB, <i>N</i> (%)	1018 (30.2)	307 (26.2)	711 (32.3)	0.133	0.029
Beta-blocker, <i>N</i> (%)	594 (17.6)	194 (16.5)	400 (18.2)	0.043	0.002
Statin, <i>N</i> (%)	590 (17.5)	153 (13.0)	437 (19.9)	0.179	0.051
Chemotherapy, <i>N</i> (%)	2038 (60.4)	782 (66.7)	1256 (57.0)	0.197	0.040
Steroid, <i>N</i> (%)	1354 (40.1)	534 (45.5)	820 (37.2)	0.169	0.019


Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; COPD, chronic obstructive pulmonary disease; CTLA-4i, cytotoxic T-lymphocyte-associated protein 4 inhibitor; NA, not applicable; PD-1i, programmed cell death protein-1 inhibitors; PD-L1i, programmed death ligand-1 inhibitors; SMD, standardized mean difference.

### 3 | RESULTS

In total, 4324 ICI users were identified. After excluding 949 patients with known DM (Figure 1), 3375 were analyzed (2202 (65.2%) males, median age 62.2 [IQR 53.8–69.5] years old), of whom 2426 (71.9%) only ever used PD-1i, 622 (18.4%) only ever used PD-L1i, four (0.1%) only ever used CTLA-4i (0.1%), and 323 (9.6%) used more than one ICI. Almost half of the patients had lung cancer (1595 patients, 45.3%). Baseline characteristics of the included patients are summarized in Table 1.


#### 3.1 | Overall burden of new-onset DM in ICI users

Over a median follow-up of 1.0 [0.4–2.4] years, new-onset DM occurred in 457 patients (13.5%), while 1563 (46.3%) died without having new-onset DM. The incidence rate of new-onset DM was 8.6 [7.8, 9.4] cases per 100 person-years. Among those who developed new-onset DM, the median time to new-onset DM was 125 [43–311] days. The cause-specific cumulative incidence of new-onset DM is visualized in Figure 2, with the 1-year risk being 10.8% [95% confidence



**FIGURE 1** Study flowchart. CTLA-4i, cytotoxic T-lymphocyte-associated protein 4 inhibitors. PD-1i, programmed cell death protein-1 inhibitors. PD-L1i, programmed death ligand-1 inhibitors.

**FIGURE 2** Cumulative incidence curve of new-onset diabetes mellitus (DM) throughout the study period. The shaded area indicates the 95% confidence interval.



interval 9.8%, 11.9%], the 2-year risk being 13.3% [12.1%, 14.5%], and the 3-year risk being 14.5% [13.3%, 15.8%].


### 3.2 | Comparing the risk of new-onset DM between sexes

During follow-up, new-onset DM occurred in 326 males (14.8%) and 131 females (11.2%). IPTW achieved acceptable balance of covariates between groups (SMD <0.2; Table 1). Males had significantly higher risk of new-onset DM (HR 1.35 [1.09, 1.67],  $p = 0.006$ ; Figure 3). Such


observation was consistent on limiting the analysis to patients with at least 1 year of follow-up ( $N = 1705$ ; HR 1.50 [1.10, 2.03],  $p = 0.010$ ), and on competing risk regression (sub-hazard ratio 1.34 [1.08, 1.66],  $p = 0.008$ ).

### 3.3 | Comparing the risk of new-onset DM for users of PD-1i and PD-L1i

As only four patients only ever used CTLA-4i, only PD-1i and PD-L1i were compared for the risk of new-onset DM. After further excluding 69 users of both PD-1i and PD-L1i



**FIGURE 3** Cumulative incidence curve of new-onset diabetes mellitus (DM) among male and female patients throughout the study period.



**FIGURE 4** Cumulative incidence curve of new-onset diabetes mellitus (DM) among users of PD-1i (programmed cell death protein-1 inhibitors) and PD-L1i (programmed death ligand-1 inhibitors) throughout the study period.

and 258 users of CTLA-4i (Figure 1), 3048 patients were analyzed (622 PD-1i users and 2426 PD-L1i users; median age 62.6 [54.5–69.8] years old; 1984 (65.1%) males). IPTW of covariates achieved acceptable balance between treatment groups (SMD <0.2; Table S2).

Over a median follow-up of 1.0 [0.4–2.3] years, new-onset DM occurred in 306 PD-1i users (12.6%) and 85 PD-L1i users; 1399 died without developing new-onset DM (45.9%). Users of PD-1i and PD-L1i did not differ significantly in the risk of new-onset DM (HR 0.81 [0.59, 1.11],  $p = 0.182$  referencing against PD-L1i; Figure 4), which was consistently observed on limiting the analysis to those with at least 1 year of follow-up ( $N = 1505$ ; HR 0.64 [0.39, 1.04],  $p = 0.073$ ), and on competing risk regression (sub-hazard ratio 0.89 [0.66, 1.21],  $p = 0.476$ ).

## 4 | DISCUSSION

In this population-based study, we quantified the risk of new-onset DM among patients with cancer receiving ICIs, with consideration given to mortality as competing risk. We showed that such risks may be higher in males but may not differ significantly between PD-1i and PD-L1i users.

Previous studies focusing on ICI-related DM have either been case reports or series,<sup>29,30</sup> relied on data from pharmacovigilance databases,<sup>31–33</sup> or adopted a case-only approach where only patients with ICI-related DM were studied.<sup>31,34</sup> As such designs are often heavily affected by selection bias and that underreporting of events is common in pharmacovigilance databases, these findings

may be seen as hypothesis-generating and may not be representative. Some have performed post hoc analysis or meta-analysis of randomized controlled trials.<sup>33</sup> While these would be ideal for comparing ICI against other therapies in terms of the risk of DM, most trials only include highly selected populations, implying that such findings are unlikely to be representative or generalizable to real-world practice. In contrast, we analyzed data from a population-based database that essentially included all patients that have ever received any ICI in Hong Kong, ensuring that our findings closely reflect real-world practice. We observed that new-onset DM has an overall incidence rate of 8.6 cases per 100 person-years. Putting these numbers in context, it was estimated that in Hong Kong, type 2 DM had an incidence rate of approximately 0.5–1 and 1–2 cases per 100 person-years among those aged 40–59 years old and those aged at least 60 years old, respectively, while the corresponding incidence rates for type 1 DM were essentially negligible for these age groups.<sup>35</sup> The substantially higher incidence rate of new-onset DM observed in this study echoed previous findings that ICI use is associated with elevated risks of DM.<sup>36</sup>

Furthermore, we observed that males had an estimated 35% higher risk of new-onset DM, which was confirmed on two sensitivity analyses. However, as we did not specifically analyze immune-related DM, our findings may have been driven at least in part by the known, higher risk of DM in males,<sup>37,38</sup> which is attributable to endogenous estrogen being protective of DM, as well as probable between-sex differences in energy partitioning, energy balance, and body composition.<sup>38</sup> While this was supported by a 2021 meta-analysis showing no significant difference between sex in immune-related adverse events among ICI users, several more recent studies have suggested otherwise with somewhat conflicting results.<sup>39,40</sup> Overall, potential between-sex differences in the risk of new-onset DM remains contentious and incompletely understood, and further investigations are warranted. On the other hand, we found no significant difference in the risk of new-onset DM between PD-1i and PD-L1i, which was consistent with a previous meta-analysis by Lu and colleagues.<sup>36</sup> Unfortunately, very few patients had received CTLA-4i in Hong Kong at the time of this study being conducted, preventing relevant comparisons. A meta-analysis has suggested that CTLA-4i may carry higher risk of immune-related adverse events than PD-1i and PD-L1i.<sup>41</sup> Further studies comparing CTLA-4i with other classes of ICIs for the risk of new-onset DM are warranted.

Our findings allow clinicians to have a better understanding of the risk of new-onset DM in patients with

cancer receiving ICIs. It is essential the risks related to ICI use are clearly communicated to patients prior to ICI initiation,<sup>42</sup> and our population-based statistics should aid clinicians in such discussions and facilitate share decision-making. Nonetheless, in addition to the between-sex and between-class differences that we have alluded to above, many gaps remain in the understanding of DM in ICI users, including its risk factors, tools for early detection and risk stratification, prognosis, and management. In particular, although ICI-related DM has mainly been described as an acute condition,<sup>43,44</sup> emerging evidence suggested that long-term or delayed-onset adverse events may occur.<sup>45,46</sup> Also, without any non-ICI-exposed group, this study was not designed to investigate any incremental long-term risk of new-onset DM associated with ICI use, and more detailed quantification in this regard remains needed. Overall, further studies of the long-term associations between ICIs and DM are warranted, and larger studies in different populations are required to validate our findings.

#### 4.1 | Strengths and limitations

Having utilized data from a population-based database, our results are representative of ICI users in Hong Kong, and are likely generalizable to other Asian regions. Additionally, we used appropriate statistical tools to properly address the impact of mortality as a competing risk which may otherwise skew estimates of cumulative incidences.<sup>28</sup> Nonetheless, this study was not devoid of limitations. First, due to the nature of the database, the data could not be individually adjudicated. This meant that it was not possible to differentiate immune-related DM from DM due to other causes (e.g., old age), which limited the interpretation of our findings. Nevertheless, our findings still provided a broad picture of the burden of new-onset DM in patients with cancer receiving ICIs which, regardless of the exact etiology and subtype of new-onset DM, remains a valuable information for clinicians and patients alike. The lack of adjudication was also unlikely to significantly affect the validity of our data, as data input was performed by treating clinicians independent of the authors, and both the CDARS and the Hong Kong Death Registry have been demonstrated to have good data accuracy and completeness.<sup>20</sup> Second, due to the nature of the database used, cancer staging and histological subtypes were not available. Third, inherent to the observational nature of this study, there may be residual or unobserved confounders. Nonetheless, we have attempted to minimize these limitations by considering as many potential confounders as possible in IPTW.

## 5 | CONCLUSIONS

In this population-based study, we quantified the burden of new-onset DM among patients with cancer receiving ICIs. The risk of new-onset DM may be higher in males, but may not differ significantly between PD-1 and PD-L1 users. Further studies are required to confirm our findings.

## LAY SUMMARY

Patients receiving immune checkpoint inhibitors have significant risks of new-onset diabetes, which may be higher in males but may not differ between specific classes of these medications.

## AUTHOR CONTRIBUTIONS

**Jeffrey Shi Kai Chan:** Conceptualization (equal); data curation (lead); formal analysis (lead); methodology (lead); visualization (lead); writing – original draft (lead); writing – review and editing (lead). **Sharen Lee:** Conceptualization (equal); investigation (equal); writing – review and editing (supporting). **Dicken Kong:** Investigation (equal); writing – review and editing (supporting). **Ishan Lakhani:** Investigation (equal); writing – review and editing (supporting). **Kenrick Ng:** Supervision (equal); writing – review and editing (supporting). **Edward Christopher Dee:** Supervision (equal); writing – review and editing (supporting). **Pias Tang:** Investigation (equal); writing – review and editing (supporting). **Yan Hiu Athena Lee:** Investigation (equal); writing – review and editing (supporting). **Danish Iltaf Satti:** Investigation (supporting); writing – review and editing (supporting). **Wing Tak Wong:** Supervision (equal); writing – review and editing (supporting). **Tong Liu:** Funding acquisition (lead); supervision (equal); writing – review and editing (supporting).

## FUNDING INFORMATION

This work was funded by the Tianjin Key Medical Discipline (Specialty) Construction Project (Project number: TJYXZDXK-029A). The funder played no role in any part of this study.

## CONFLICTS OF INTEREST

ECD is funded in part through the Cancer Center Support Grant from the National Cancer Institute (P30 CA008748). None of the other authors had any relationship with industry or conflict of interest.

## DATA AVAILABILITY STATEMENT

All underlying data is available on reasonable request to the corresponding authors.

## PATIENT CONSENT STATEMENT

Requirement for individual patient consent was waived as only retrospective data were used.

## ETHICAL APPROVAL

This study was approved by The Joint Chinese University of Hong Kong – New Territories East Cluster Clinical Research Ethics Committee.

## ORCID

Jeffrey Shi Kai Chan  <https://orcid.org/0000-0003-0231-2393>

Ishan Lakhani  <https://orcid.org/0000-0001-7566-9700>

Edward Christopher Dee  <https://orcid.org/0000-0001-6119-0889>

Yan Hiu Athena Lee  <https://orcid.org/0000-0003-0740-1598>

Tong Liu  <https://orcid.org/0000-0003-0482-0738>

## REFERENCES

1. Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. *Nat Commun.* 2020;11(1):1-3.
2. Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. *Front Pharmacol.* 2017;8(AUG):561.
3. Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. *Trends Immunol.* 2006;27(4):195-201.
4. Yang H, Yao Z, Zhou X, Zhang W, Zhang X, Zhang F. Immune-related adverse events of checkpoint inhibitors: insights into immunological dysregulation. *Clin Immunol.* 2020;213:108377.
5. Weinmann SC, Pisetsky DS. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. *Rheumatology.* 2019;58(Supplement\_7):vii59-vii67.
6. Stamatouli AM, Quandt Z, Perdigoto AL, et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. *Diabetes.* 2018;67(8):1471-1480.
7. Hughes J, Vudattu N, Sznol M, et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. *Diabetes Care United States.* 2015;38:e55-e57.
8. Myers G. Immune-related adverse events of immune checkpoint inhibitors: a brief review. *Curr Oncol.* 2018;25(5):342-347.
9. Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. *Cell.* 2018;175(2):313-326.
10. Chan JSK, Lakhani I, Lee TTL, et al. Cardiovascular outcomes and hospitalizations in Asian patients receiving immune checkpoint inhibitors: a population-based study. *Curr Probl Cardiol.* 2022;48:101380.
11. Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. *Nat Rev Clin Oncol.* 2019;16(9):563-580.
12. Zhou J, Lee S, Lakhani I, et al. Adverse Cardiovascular Complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1)

- inhibitors: a propensity-score matched Cohort Study with competing risk analysis. *Cardio-Oncology (London, England)*. 2022;8(1):5.
13. Dong M, Yu T, Zhang Z, et al. ICIs-related cardiotoxicity in different types of cancer. *J Cardiovasc Dev Dis*. 2022;9(7):203.
  14. Zhou J, Chau YLA, Yoo JW, et al. Liver immune-related adverse effects of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity score matched study with competing risk analyses. *Clin Oncol (R Coll Radiol)*. 2022;34(7):e316-e317.
  15. Tan MH, Iyengar R, Mizokami-Stout K, et al. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. *Clin Diabetes Endocrinol*. 2019;5(1):1.
  16. Lee S, Tse G. A patient with Atezolizumab-induced autoimmune diabetes mellitus presenting with diabetic ketoacidosis. *Cardiovasc Innov Appl*. 2021;6(1):45-50.
  17. Wu Y, Ju Q, Jia K, et al. Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors). *Int J Cancer*. 2018;143(1):45-51.
  18. Wang C, Qiao W, Jiang Y, et al. Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non-small cell lung cancer. *Cancer Med*. 2019;8(8):4023-4031.
  19. Kong X, Yang Y, Gao J, et al. Overview of the health care system in Hong Kong and its referential significance to mainland China. *J Chinese Med Assoc*. 2015;78(10):569-573.
  20. Tsoi MF, Chung MH, Cheung BMY, Lau CS, Cheung TT. Epidemiology of gout in Hong Kong: a population-based study from 2006 to 2016. *Arthritis Res Ther*. 2020;22(1):1-9.
  21. Tse G, Zhou J, Lee S, et al. Relationship between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and COVID-19 incidence or severe disease. *J Hypertens*. 2021;39(8):1717-1724.
  22. Chan JSK, Tang P, Hui JMH, et al. Association between duration of gonadotrophin-releasing hormone agonist use and cardiovascular risks: a population-based competing-risk analysis. *Prostate*. 2022;82:1477-1480.
  23. Wai AKC, Wong CKH, Wong JYH, et al. Changes in emergency department visits, diagnostic groups, and 28-day mortality associated with the COVID-19 pandemic: a territory-wide, retrospective. *Cohort Study Ann Emerg Med*. 2022;79(2):148-157.
  24. Choi AWM, Wong JYH, Kam CW, Lau CL, Wong JKS, Lo RTF. Injury patterns and help-seeking behavior in Hong Kong male intimate partner violence victims. *J Emerg Med*. 2015;49(2):217-226.
  25. American Diabetes Association Professional Practice Committee. 2. Classification and diagnosis of diabetes: standards of medical Care in Diabetes—2022. *Diabetes Care*. 2022;45(Supplement\_1):S17-S38.
  26. Aalen OO, Johansen S. An empirical transition matrix for non-homogeneous Markov chains based on censored observations. *Scand J Stat*. 1978;5(3):141-150.
  27. Chan JSK, Lee YHA, Liu K, et al. Long-term cardiovascular burden in prostate cancer patients receiving androgen deprivation therapy. *Eur J Clin Invest*. 2022:e13932. <https://doi.org/10.1111/eci.13932>
  28. Nielsen RO, Bertelsen ML, Ramskov D, et al. Time-to-event analysis for sports injury research part 2: time-varying outcomes. *Br J Sports Med*. 2019;53(1):70-78.
  29. Akturk HK, Kahramangil D, Sarwal A, Hoffecker L, Murad MH, Michels AW. Immune checkpoint inhibitor-induced type 1 diabetes: a systematic review and meta-analysis. *Diabet Med*. 2019;36(9):1075-1081.
  30. Lin C, Li X, Qiu Y, Chen Z, Liu J. PD-1 inhibitor-associated type 1 diabetes: a case report and systematic review. *Front Public Heal*. 2022;10:2669.
  31. Bastin M, Allouchery M, Sassier M, et al. Characteristics of insulinopenic and non insulinopenic diabetes related to immune checkpoint inhibitors: a French pharmacovigilance study. *Therapie*. 2021;76(6):695-703.
  32. Liu J, Zhou H, Zhang Y, et al. Reporting of immune checkpoint inhibitor therapy-associated diabetes, 2015–2019. *Diabetes Care*. 2020;43(7):e79-e80.
  33. Zhu J, Luo M, Liang D, et al. Type 1 diabetes with immune checkpoint inhibitors: a systematic analysis of clinical trials and a pharmacovigilance study of postmarketing data. *Int Immunopharmacol*. 2022;110:109053.
  34. Muniz TP, Araujo DV, Savage KJ, et al. CANDIED: a pan-Canadian cohort of immune checkpoint inhibitor-induced insulin-dependent diabetes mellitus. *Cancers (Basel)*. 2021;14(1):89.
  35. Luk AOY, Ke C, Lau ESH, et al. Secular trends in incidence of type 1 and type 2 diabetes in Hong Kong: a retrospective cohort study. *PLoS Med*. 2020;17(2):e1003052.
  36. Lu J, Yang J, Liang Y, Meng H, Zhao J, Zhang X. Incidence of immune checkpoint inhibitor-associated diabetes: a meta-analysis of randomized controlled studies. *Front Pharmacol*. 2019;10:1453.
  37. Östman J, Lönnberg G, Arnqvist HJ, et al. Gender differences and temporal variation in the incidence of type 1 diabetes: results of 8012 cases in the nationwide diabetes incidence study in Sweden 1983-2002. *J Intern Med*. 2008;263(4):386-394.
  38. Tramunt B, Smati S, Grandgeorge N, et al. Sex differences in metabolic regulation and diabetes susceptibility. *Diabetologia*. 2020;63(3):453-461.
  39. Jang SR, Nikita N, Banks J, et al. Association between sex and immune checkpoint inhibitor outcomes for patients with melanoma. *JAMA Netw Open*. 2021;4(12):e2136823.
  40. Chen C, Zhang C, Jin Z, Wu B, Xu T. Sex differences in immune-related adverse events with immune checkpoint inhibitors: data mining of the FDA adverse event reporting system. *Int J Clin Pharmacol*. 2022;44(3):689-697.
  41. Song P, Zhang D, Cui X, Zhang L. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients. *Thorac Cancer*. 2020;11(9):2406-2430.
  42. Cheema PK, Iafolla MAJ, Nematollahi M, et al. A guide to implementing immune checkpoint inhibitors within a cancer program: experience from a large Canadian community Centre. *Curr Oncol*. 2022;29(2):869-880.
  43. Tsang VHM, McGrath RT, Clifton-Bligh RJ, et al. Checkpoint inhibitor-associated autoimmune diabetes is distinct from type 1 diabetes. *J Clin Endocrinol Metab*. 2019;104(11):5499-5506.
  44. Quandt Z, Young A, Anderson M. Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. *Clin Exp Immunol*. 2020;200(2):131-140.
  45. Horisberger K, Portenkirchner C, Rickenbacher A, Biedermann L, Gubler C, Turina M. Long-term immune-related adverse events after discontinuation of immunotherapy. *Immunotherapy*. 2021;13(9):735-740.

46. Owen CN, Bai X, Quah T, et al. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. *Ann Oncol off J Eur Soc Med Oncol*. 2021;32(7):917-925.

## SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Chan JSK, Lee S, Kong D, et al. Risk of diabetes mellitus among users of immune checkpoint inhibitors: A population-based cohort study. *Cancer Med*. 2023;00:1-10. doi:[10.1002/cam4.5616](https://doi.org/10.1002/cam4.5616)